Lessons to be learned from recent studies of anaemia management in chronic kidney disease

Philip A. Kalra*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

Abstract

Anaemia is extremely common in patients with chronic kidney disease (CKD). Causes are multifactorial but erythropoietin deficiency, iron deficiency or diminished availability and chronic inflammation are pre-eminent. For over two decades it has been possible to correct the anaemia of patients with CKD with combinations of iron therapy and erythropoiesis-stimulating agents (ESA) with relative ease. Results of recent studies, however, have indicated that haemoglobin targets need to be revised and that more consideration should be directed to individualised treatment dependent upon the patient’s haemoglobin response, ESA dosage and level of co-morbidity.
Original languageEnglish
Pages (from-to)s1-s15
Number of pages16
JournalBritish Journal of Cardiology
Volume18
Issue numberSUPPL. 2
Publication statusPublished - Aug 2011

Fingerprint

Dive into the research topics of 'Lessons to be learned from recent studies of anaemia management in chronic kidney disease'. Together they form a unique fingerprint.

Cite this